Novel psychoactive substances (NPS) use in severe mental illness (SMI) patients: Potential changes in the phenomenology of psychiatric diseases

A systematic review of the effects of novel psychoactive substances ‘legal highs’ on people with severe mental illness

(2016) R. Gray et al.   Journal of Psychiatric and Mental Health Nursing

Chronic non-fatal Datura abuse in a patient of paranoid schizophrenia: A case report

(2015) Sourav Khanra et al.   ADDICTIVE BEHAVIORS

Prevalence of substance use disorders in psychiatric patients: a nationwide Danish population-based study

(2015) Nanna Gilliam Toftdahl et al.   SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY

Novel psychoactive substances of interest for psychiatry

(2015) Fabrizio Schifano et al.   World Psychiatry

Novel Psychoactive Substances in Young Adults with and without Psychiatric Comorbidities

(2014) Giovanni Martinotti et al.   Biomed Research International

Bath Salts Intoxication: A Case Series

(2013) Syed F. Imam et al.   JOURNAL OF EMERGENCY MEDICINE

Synthetic cannabinoid JWH-018 and psychosis: An explorative study

(2011) Susanna Every-Palmer   DRUG AND ALCOHOL DEPENDENCE

Acute liver failure following recreational use of psychotropic “head shop” compounds

(2010) S. Fröhlich et al.   IRISH JOURNAL OF MEDICAL SCIENCE

The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway

(2009) O. D. Howes et al.   SCHIZOPHRENIA BULLETIN

Specificity of Bipolar Spectrum Conditions in the Comorbidity of Mood and Substance Use Disorders

(2008) Kathleen R. Merikangas et al.   ARCHIVES OF GENERAL PSYCHIATRY

Role of Dopamine in the Motivational and Cognitive Control of Behavior

(2008) Roshan Cools   NEUROSCIENTIST